eli lilly oral glp-1 to seek approval of new weight-loss drug this year FDA just approved orforglipron (Foundayo),

If GLP-1 receptor modulation proves effective in reducing cravings and relapse risk, it could inaugurate an entirely new class of addiction therapeutics rooted in metabolic-neuroendocrine mechanisms

GLP-1 plays a powerful role in how our bodies manage glucose and appetite

Even if you end up at the same weight as you were before, metabolically, you are likely a lot less healthy, she says

Licensed weight loss medicines such as orlistat, semaglutide (Wegovy), and naltrexone/bupropion (Mysimba) do not typically alter the menstrual cycle through direct hormonal action

GLP-1 medications commonly cause gastrointestinal side effects, particularly during treatment initiation or dose escalation

DSP declares associations to Abbott, Alkaloid, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and Worwag Pharma